California, March 14, 2017 -- 1PM Industries, Inc. (OTC: OPMZ) announced today that the Company has contracted with a new privately held company that wishes to begin trading publicly.
CEO Joseph Wades stated, “We are pleased to announce that we have contracted with a company that is involved with the growth and development of Senior Centers in the state of California. In fact, the primary leadership of this company was involved in a similar venture several years ago that went public at over the counter status and eventually reached the New York Stock Exchange.”
Mr. Wade went on to say, “As we mentioned in the last press release, there are multiple revenue streams that we realize from each account. Collectively, we fully expect to generate well over $800,000.00 from this one contract. We have several others in the pipeline, but our primary focus at least for the next three weeks will be to get this one processed and headed in the right direction.”
Mr. Wade finished up with, “The $1,300,000 revenue that was generated as part of the first contract for 2017 along with the revenue generated from this new contract will be reflected in our upcoming filings. In addition, we have several other clients that are at different stages of the process; one in particular that should be contracting with us early second quarter. We thank you for your interest and support as a shareholder and we will keep you all posted on future developments.”
About 1pm Industries: 1pm Industries, Inc. helps private companies to become public trading entities. 1pm Industries ensures that each client is shepherded through the process of becoming a publicly traded entity and then acts as a consultant until such time that the company is capable of managing the necessary activities and requirements on their own. In many cases, 1pm Industries locks in long term contractual agreements even after a company is trading publicly depending on the experience level of the management team.
Notice Regarding Forward-Looking Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Actual results could differ from those projected in any forward-looking statements due to numerous factors. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual and interim reports.
Contacts 1PM Industries, Inc. (424) 253-9991 [email protected]


Trump Blocks HieFo’s Emcore Chip Assets Deal Over National Security Concerns
Starlink Plans Satellite Orbit Reconfiguration in 2026 to Boost Space Safety
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares
Target Stock Rallies as Activist Interest Sparks Hopes for Strategic Change
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro
Samsung Signals Comeback With HBM4 Chips as AI Market Heats Up
Neuralink Plans High-Volume Brain Implant Production and Fully Automated Surgery by 2026
Drugmakers Plan 2026 U.S. Price Increases on Over 350 Branded Medications Despite Political Pressure
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 



